Search

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more

The importance of education and collaboration for the treatment of patients

This article is written in the context of EHA’s membership of the European Alliance for Personalised Medicine (EAPM) where EHA takes a lead in the development of a strategy for education in personalized medicine. Read the full article here

Read more

EHA-ECL led statement calls for protection of the Hospital Exemption

The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.

Read more

EHA Research Grants

The call for applications is closed. EHA Research Grants support talented junior researchers in advancing their career—for example, by helping them move towards becoming the leader of a research group.

Read more

Press Release: Economic burden of blood disorders in EU is €23 billion

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more

“Follow your dreams! Go for it!” – Verena Gaidzik, woman in hematology/EHA volunteer

Verena Gaidzik is a physician scientist in the department of Internal Medicine III (Head: Prof. Dr. Hartmut Döhner) at the University Hospital of Ulm. She has board certifications in internal medicine, hematology and oncology as well as palliative medicine.

Read more

Cancer Medicines Forum workshop April 5: a way forward for treatment optimization

The Cancer Medicines Forum (CMF) is hosted by the European Medicines Agency (EMA) in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC).

Read more